Sionna Therapeutics Inc(SION) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:09 PM ET (Korea 10/31 05:09)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -2.17 | Insider Own | 47.89% | Shs Outstand | 45.2M | Perf Week | 7.5% |
| Market Cap | 0.17B | Forward P/E | - | EPS next Y | 7.52% | Insider Trans | -17.04% | Shs Float | 23.6M | Perf Month | -24.12% |
| Enterprise Value | -0.03B | PEG | - | EPS next Q | -0.64 | Inst Own | 65.68% | Short Float | 15.6% | Perf Quarter | -92.14% |
| Income | -0.10B | P/S | - | EPS this Y | -31.87% | Inst Trans | 12.57% | Short Ratio | 1.62 | Perf Half Y | -90.11% |
| Sales | 0.00B | P/B | 0.66 | EPS next 5Y | -11.4% | ROA | -30.66% | Short Interest | 3.68M | Perf YTD | -90.59% |
| Book/sh | 5.88 | P/C | 0.83 | EPS past 3/5Y | -22.66% - | ROE | -32.34% | 52W High | -92.96% ($54.97) | Perf Year | -89.82% |
| Cash/sh | 4.67 | P/FCF | - | Sales past 3/5Y | - | ROIC | -35.74% | 52W Low | 9.01% ($3.55) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -26.18% | Gross Margin | - | Volatility(W/M) | 6.95% 7.58% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.43 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 20.05 | EPS Q/Q | -61.68% | Profit Margin | - | RSI (14) | 31.21 | Recom | 2.82 |
| Dividend Gr. 3/5Y | - | Current Ratio | 20.05 | Sales Q/Q | - | SMA20 | -8.13% ($4.21) | Beta | 1.04 | Target Price | $21.57 |
| Payout | - | Debt/Eq | 0.03 | Earnings | 2026/8/6 | SMA50 | -28.94% ($5.45) | Rel Volume | 0.24 | Prev Close | $4 |
| Employees | 59 | LT Debt/Eq | 0.03 | EPS/Sales Surpr. | -1.54% - | SMA200 | -87.15% ($30.12) | Avg Volume(3M) | 2.27M | Price | $3.87 |
| IPO | 2025/2/7 | Option/Short | Yes/Yes | Trades | 3678 | Volume | 534,078 | Change | -3.25% |
🧬 This is a U.S. clinical-stage biotech company developing treatments for cystic fibrosis. It develops therapies through a differentiated approach that targets the protein responsible for cystic fibrosis, and is a recently listed biotech with candidates in its pipeline. As a growth-stage biotech aimed at the unmet genetic disease of cystic fibrosis, the stock is driven by business progress and market sentiment.
Over the past 1 year, on the lower side
93% below its 1-year high.
Traded less than usual. That is 24% of its average volume.
SION has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -31.9% this year.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 65.7%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #312 of 597 in the industry
Based on market cap of $175M.
TRDA#311 Entrada Therapeutics Inc $177M PER - SION#312 Sionna Therapeutics Inc $175M PER - 
MDWD#313 MediWound Ltd $172M PER - 
IVVD#314 Invivyd Inc $171M PER - 
ORMP#315 Oramed Pharmaceuticals Inc $171M PER 1.0 
FAQ
What kind of company is SION?
SION belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of SION?
The market cap of SION is approximately $175M, ranking 4,112 within its sector.
What is the 52-week high and low for SION?
SION has recorded a 52-week high of $54.97 and a low of $3.55.
